The offering represents substantial near-term dilution for existing shareholders, despite funding a critical Phase 3 trial. Monitor for potential downward pressure on the stock price ahead of closing, and watch for updates on trial timelines and enrollment progress.
Price Chart
Executive Summary
Altimmune announced the pricing of a public offering of common stock and pre-funded warrants, along with accompanying warrants, expected to raise approximately $225 million in gross proceeds. The funds will be used to finance its upcoming Phase 3 trial in MASH, working capital, and general corporate purposes.
Key Financial Metrics
Key Facts
- Altimmune is raising approximately $225 million in gross proceeds through a public offering.
- The offering includes 64.25 million shares of common stock and accompanying warrants, plus up to 10.75 million pre-funded warrants with accompanying warrants.
- Each common stock unit is priced at $3.00; each pre-funded warrant unit is priced at $2.999.
- Accompanying warrants have an exercise price of $3.00 per share and expire upon the earlier of five years or 45 days after a successful Phase 3 MASH data readout.
- Proceeds will fund the Phase 3 MASH trial, working capital, and general corporate purposes.
Financial Impact
$225 million gross proceeds, significant dilution expected due to large share issuance and low exercise price of pre-funded warrants.
Risk Factors
- Significant equity dilution from issuance of up to ~75 million new shares (including pre-funded warrants) and additional warrants exercisable at $3.00.
- Failure to achieve positive Phase 3 MASH data could render the accompanying warrants worthless and jeopardize future funding.
- Market conditions could delay or prevent closing, increasing financial uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3279527 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $2.97 $2.67 | ▼ −10.10% | ▼ −12.05% | $2.09 (−29.63%) |
Aug 12, 2026 10w ago | 8-K | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 12, 2026 10w ago | Press Release | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 6, 2026 11w ago | Institutional Cluster | $3.01 $2.88 | ▼ −4.32% | ▼ −5.53% | $2.09 (−30.56%) |
Aug 5, 2026 11w ago | Press Release | $3.03 $2.93 | ▼ −3.30% | ▼ −3.65% | $2.09 (−31.02%) |
Aug 3, 2026 12w ago | Press Release | $3.00 $3.05 | ▲ +1.67% | ▼ −0.36% | $2.09 (−30.33%) |
Jul 28, 2026 12w ago | 8-K | $2.99 $3.00 | ▲ +0.33% | ▼ −1.93% | $2.09 (−30.10%) |
May 28, 2026 21w ago | Press Release | $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.09 (−31.92%) |
May 27, 2026 21w ago | Press Release | $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.09 (−29.87%) |
May 13, 2026 23w ago | 8-K | $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.09 (−30.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers